Lantern Pharma's total assets for Q2 2025 were $17.42M, a decrease of -17.43% from the previous quarter. LTRN total liabilities were $4.90M for the fiscal quarter, a 13.38% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.